- Home
- EBS vs MREO Comparison
EBS vs MREO Comparison
Compare EBS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- MREO
- Stock Information
- Founded
- EBS 1998
- MREO 2015
- Country
- EBS United States
- MREO United Kingdom
- Employees
- EBS N/A
- MREO N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- MREO Health Care
- Exchange
- EBS Nasdaq
- MREO Nasdaq
- Market Cap
- EBS 393.9M
- MREO 369.2M
- IPO Year
- EBS 2006
- MREO N/A
- Fundamental
- Price
- EBS $6.38
- MREO $2.42
- Analyst Decision
- EBS Strong Buy
- MREO Strong Buy
- Analyst Count
- EBS 3
- MREO 7
- Target Price
- EBS $14.33
- MREO $7.71
- AVG Volume (30 Days)
- EBS 1.1M
- MREO 1.5M
- Earning Date
- EBS 05-07-2025
- MREO 05-19-2025
- Dividend Yield
- EBS N/A
- MREO N/A
- EPS Growth
- EBS N/A
- MREO N/A
- EPS
- EBS N/A
- MREO N/A
- Revenue
- EBS $965,400,000.00
- MREO N/A
- Revenue This Year
- EBS N/A
- MREO N/A
- Revenue Next Year
- EBS $19.88
- MREO $56.11
- P/E Ratio
- EBS N/A
- MREO N/A
- Revenue Growth
- EBS N/A
- MREO N/A
- 52 Week Low
- EBS $4.02
- MREO $1.58
- 52 Week High
- EBS $15.10
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- EBS 65.88
- MREO 50.79
- Support Level
- EBS $4.71
- MREO $2.28
- Resistance Level
- EBS $5.70
- MREO $2.75
- Average True Range (ATR)
- EBS 0.38
- MREO 0.16
- MACD
- EBS 0.13
- MREO 0.00
- Stochastic Oscillator
- EBS 85.77
- MREO 32.65
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).